In this study, we identified 12 carriers of PALB2 pathogenic variants in 1556 Chinese patients with BRCA1/2-negative early-onset breast cancer, resulting in a mutation frequency of 0.77%. This evidence concerns the gene PALB2 and breast carcinoma.